Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057017 · ClinicalTrials.gov registry record · Phase 2
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
A Phase 2 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01057017 is a Phase 2 study that was terminated before completion, run by Brown University. The registered enrollment target is 5 participants.
The verdict
NCT01057017, a Phase 2 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression.Primary Objective: To determine the safety of every 3 week panitumumab and bevacizumab as maintenance therapy for patients with metastatic colorectal cancer.
Interventions
- BIOLOGICAL intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057017
The ClinicalTrials.gov registry entry for NCT01057017 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which intervention is the first listed.
NCT01057017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057017 about?
NCT01057017 is a clinical study titled "First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras". Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression.Primary Objective: To determine the safety of every 3 week panitumumab and bevacizumab as maintenance therapy for pa...
What is the current status of trial NCT01057017?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01057017?
The interventions under investigation include: intervention (BIOLOGICAL).
Who is sponsoring clinical trial NCT01057017?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.